ホーム › 非小細胞肺癌 › ノースカロライナ › Winston-Salem
Winston-Salem、NCにおける非小細胞肺癌の臨床試験
Winston-Salemとその周辺地域(約30マイル以内)の拠点で、非小細胞肺癌に関する12件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト(英語)
ここで研究参加者を募集していますか? このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9マイル先
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
被験者募集中第3相
- Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
被験者募集中第3相
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
被験者募集中第3相
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
被験者募集中第2相
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
被験者募集中第2相
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
被験者募集中第3相
- Atrium Health Wake Forest Baptist, Winston-Salem
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
被験者募集中観察研究
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
被験者募集中第2相
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Wake Forest NCORP Research Base, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Winston-Salem
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Winston-Salemにおける他の研究
- がん(全種類)19件の研究
- 急性骨髄性白血病18件の研究
- 多発性骨髄腫14件の研究
- 乳がん14件の研究
- 心血管疾患14件の研究
- COPD10件の研究
- 卵巣がん10件の研究
- 2型糖尿病9件の研究
- 骨髄異形成症候群9件の研究
- 膠芽腫8件の研究
- 慢性リンパ性白血病8件の研究
- 肺がん8件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。